Journal of Neural Transmission

, Volume 109, Issue 4, pp 489-501

First online:

A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by l-dopa

  • E. R. BruntAffiliated withDepartment of Neurology, University Hospital, Groningen, The Netherlands
  • , D. J. BrooksAffiliated withDivision of Neuroscience, Imperial College School of Medicine, Hammersmith Hospital, London, United Kingdom
  • , A. D. KorczynAffiliated withSieratzki Chair of Neurology, Sackler Faculty of Medicine, Tel-Aviv University, Israel
  • , J.-L. MontastrucAffiliated withDepartment of Clinical Pharmacology, Faculty of Medicine, Toulouse, France
  • , F. StocchiAffiliated withDepartment of Neuroscience and "Neuromed", University "la Sapienza", Rome, Italy
  • , on behalf of the 043 Study Group

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access



To compare the safety and efficacy of ropinirole and bromocriptine as adjunct therapy in patients with Parkinson's disease (PD) not optimally controlled by L-dopa.


A randomised, double-blind trial in which 555 patients were assigned to three treatment groups according to the level of daily dosage of L-dopa, presence of motor fluctuations, and use of dopamine agonist before study entry. Patient response was defined as at least a 20% reduction in daily L-dopa dose plus: for patients with no prior treatment and no motor fluctuations, a 20% reduction in UPDRS motor score; for patients with motor fluctuations, a 20% reduction in time spent "off"; and for patients already taking an agonist, an improvement on the CGI scale.


Safety assessments showed no significant differences in the two treatment groups for patients without prior dopamine-agonist therapy. In the group of patients with prior dopamine-agonist therapy, more patients reported adverse events in the ropinirole group (90% versus 79%, p < 0.001). The proportions of responders tended to be higher in ropinirole groups compared with bromocriptine groups and, in the subgroup with motor fluc-tuations, this difference was statistically significant (9.1% versus 0.0%, respectively; p < 0.05).


Both drugs were well tolerated. In patients receiving a relatively high dose of L-dopa and requiring the addition of a dopamine agonist to control motor fluctuations or dyskinesias, ropinirole was significantly more effective than bromocriptine.

Keywords: Parkinson's disease ropinirole bromocriptine drug therapy.